Fig. 7
(a) Human squamous carcinoma cells (SCC-25, CRL-1628™, ATCC) before bismuth selenide addiction. (b) Human squamous carcinoma cells (SCC-25, CRL-1628™, ATCC) 24 h after bismuth selenide 6.25 µg/ml addiction.
Fig. 7 | Scientific Reports
(a) Human squamous carcinoma cells (SCC-25, CRL-1628™, ATCC) before bismuth selenide addiction. (b) Human squamous carcinoma cells (SCC-25, CRL-1628™, ATCC) 24 h after bismuth selenide 6.25 µg/ml addiction.
